(TheNewswire)

Brossard, Quebec TheNewswire – December 1, 2025 CHARBONE CORPORATION (TSXV: CH,OTC:CHHYF; OTCQB: CHHYF; FSE: K47) (‘ CHARBONE ‘ or the ‘ Company ‘), a North American producer and distributor specializing in clean Ultra High Purity (‘ UHP ‘) hydrogen and strategic industrial gases, is pleased to announce the successful completion of equipment installation for Phase 1A at its Sorel-Tracy site and, in accordance with the announced schedule, the production of its first hydrogen molecule .

During the last weekend of November, CHARBONE’s technical teams conducted the first hydrogen production tests , following the commissioning of the company’s first local clean UHP hydrogen production module in Quebec. The initial results confirm the system is properly functioning, validating the initial performance parameters.

Management Statement

‘ The completion of the Phase 1A installation and the successful completion of the first hydrogen production tests are key milestones for CHARBONE ,’ said Dave B. Gagnon, CEO of CHARBONE . ‘ These accomplishments demonstrate our teams’ ability to execute rigorously. We are now entering the commercial production phase .’

The first clean UHP hydrogen project in Quebec and a model for North America

The modular plant in Sorel-Tracy represents the first local and decentralized clean UHP hydrogen production facility in Quebec , in line with CHARBONE’s vision of building an integrated North American network for the production and distribution of clean and strategic gases. For more information on the Company’s five-phase roadmap, the modular configuration of the plant, and its economic outlook, please review the investor presentation available on CHARBONE’s website .

About CHARBONE CORPORATION

CHARBONE is a developer and producer of clean Ultra High Purity (UHP) hydrogen with a growing industrial gas distribution platform. Through a modular approach, CHARBONE is focused on developing a network of clean hydrogen production facilities throughout North America and select markets abroad, starting with its flagship Sorel-Tracy project in Quebec. The Company’s integrated model reduces risk, enhances scalability, and enables diversified revenue streams through partnerships in helium and other specialty gases. CHARBONE is committed to supporting the global transition to a lower-carbon economy by providing accessible, decentralized clean hydrogen and specialty gas solutions while supporting underserved industrial gas customers and accelerating the shift to localized clean energy. CHARBONE is listed on the TSX Venture Exchange (TSXV: CH,OTC:CHHYF) , the OTC Markets (OTCQB: CHHYF) , and the Frankfurt Stock Exchange (FSE: K47) . For more information, please visit: www.charbone.com .

Forward-Looking Statements

This news release contains statements that are ‘forward-looking information’ as defined under Canadian securities laws (‘forward-looking statements’). These forward-looking statements are often identified by words such as ‘intends’, ‘anticipates’, ‘expects’, ‘believes’, ‘plans’, ‘likely’, or similar words. The forward-looking statements reflect management’s expectations, estimates, or projections concerning future results or events, based on the opinions, assumptions and estimates considered reasonable by management at the date the statements are made. Although Charbone believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements involve risks and uncertainties, and undue reliance should not be placed on forward-looking statements, as unknown or unpredictable factors could cause actual results to be materially different from those reflected in the forward-looking statements. The forward-looking statements may be affected by risks and uncertainties in the business of Charbone. These risks, uncertainties and assumptions include, but are not limited to, those described under ‘Risk Factors’ in the Corporation’s Filing Statement dated March 31, 2022, which is available on SEDAR at www.sedar.com; they could cause actual events or results to differ materially from those projected in any forward-looking statements.

Except as required under applicable securities legislation, Charbone undertakes no obligation to publicly update or revise forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release .

Copyright (c) 2025 TheNewswire – All rights reserved.

Heliostar Metals Ltd. (TSXV: HSTR,OTC:HSTXF) (OTCQX: HSTXF) (FSE: RGG1) (‘Heliostar’ or the ‘Company’) is pleased to announce that Mr James Perry has succeeded the retiring Mr. Jacques Vaillancourt as Chairman at the Company’s Annual General & Special Meeting (‘AGM’) held on November 26th, 2025.

Heliostar’s new Chairman Mr. James Perry commented, ‘I am excited to join Heliostar at this important inflection point. The Company has built a strong foundation through disciplined operations and strategic acquisitions, and I look forward to working closely with the experienced Board and management team as we advance the next phase of growth. Heliostar has the ingredients to become a leading gold producer in the Americas. I will draw on my experience to help steer the Company’s disciplined growth, reinforce strong governance practices, and create lasting value for our shareholders and host communities.’

Charles Funk, President and & CEO, stated – ‘I once again thank our retiring chair for his long service to Heliostar. I strongly welcome James as our new Chairman at a time of considerable growth. Having worked with James previously at Newcrest Mining, I know his ambition for our Company, his growth mindset and the high regard in which he is held across the industry. We are delighted to attract someone of his caliber as we continue advancing toward our goal of becoming a 500,000 ounce per year producer by the end of this decade.’

Mr. Perry is currently President of Sweetwater Royalties, one of the largest landowners in the United States, majority-owned by Orion Resource Partners following its acquisition of Sweetwater’s extensive land and mineral portfolio from Occidental Petroleum in 2020 for approximately US$1.3 billion. Sweetwater’s vast mineral position extends across more than 4.5 million mineral acres in Wyoming, Utah, Colorado, and Michigan, providing an expansive royalty platform spanning industrial minerals, base metals, and renewable-energy opportunities.

Mr. Perry has over 17 years of global mining and resources experience across Asia, Africa, and the Americas, spanning business development, corporate strategy and governance, legal and permitting, ESG, and operations. He spent a decade at Newcrest Mining – one of the world’s largest gold mining companies headquartered in Australia – serving as Business Development Manager and Corporate Counsel. Newcrest was acquired for approximately US$19 billion by Newmont Mining in 2023. Mr. Perry has extensive international experience managing large and complex transactions, including leading Newcrest’s entry into Ecuador and its investment in Lundin Gold’s world-class Fruta del Norte gold district. He possesses broad expertise in project evaluation and negotiation across diverse sectors and jurisdictions. He is a lawyer and holds an M.Sc. in History and International Relations from the London School of Economics.

Incentive plan issuance

Heliostar further announces that, pursuant to the Company’s Omnibus Equity Incentive Compensation Plan, it has granted 250,000 stock options (‘Options’) at an exercise price of $2.63 and 200,000 restricted share units (each, an ‘RSU’) to directors, officers and consultants of the Company. The Options are exercisable for a period of five years and will vest over the next three years. The RSUs will vest in three equal annual instalments commencing on the first anniversary of the grant date.

About Heliostar Metals Ltd.

Heliostar is a gold mining company with production from operating mines in Mexico. This includes the La Colorada Mine in Sonora and the San Agustin Mine in Durango. The Company also has a strong portfolio of development and exploration stage projects in Mexico and the USA. These include the Ana Paula project in Guerrero, the Cerro del Gallo project in Guanajuato, the San Antonio project in Baja Sur, all in Mexico and the Unga project in Alaska, USA.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain ‘Forward-Looking Statements’ within the meaning of the United States Private Securities Litigation Reform Act of 1995 and ‘forward-looking information’ under applicable Canadian securities laws. When used in this news release, the words ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘target’, ‘plan’, ‘forecast’, ‘may’, ‘would’, ‘could’, ‘schedule’ and similar words or expressions, identify forward-looking statements or information. These forward-looking statements or information relate to, among other things, the Company’s annual production goals.

Forward-looking statements and forward-looking information relating to the terms and completion of the Facility, any future mineral production, liquidity, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the receipt of necessary approvals, price of metals; no escalation in the severity of public health crises or ongoing military conflicts; costs of exploration and development; the estimated costs of development of exploration projects; and the Company’s ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

These statements reflect the Company’s respective current views with respect to future events and are necessarily based upon a number of other assumptions and estimates that, while considered reasonable by management, are inherently subject to significant business, economic, competitive, political, and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements or forward-looking information and the Company has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: precious metals price volatility; risks associated with the conduct of the Company’s mining activities in foreign jurisdictions; regulatory, consent or permitting delays; risks relating to reliance on the Company’s management team and outside contractors; risks regarding exploration and mining activities; the Company’s inability to obtain insurance to cover all risks, on a commercially reasonable basis or at all; currency fluctuations; risks regarding the failure to generate sufficient cash flow from operations; risks relating to project financing and equity issuances; risks and unknowns inherent in all mining projects, including the inaccuracy of reserves and resources, metallurgical recoveries and capital and operating costs of such projects; contests over title to properties, particularly title to undeveloped properties; laws and regulations governing the environment, health and safety; the ability of the communities in which the Company operates to manage and cope with the implications of public health crises; the economic and financial implications of public health crises, ongoing military conflicts and general economic factors to the Company; operating or technical difficulties in connection with mining or development activities; employee relations, labour unrest or unavailability; the Company’s interactions with surrounding communities; the Company’s ability to successfully integrate acquired assets; the speculative nature of exploration and development, including the risks of diminishing quantities or grades of reserves; stock market volatility; conflicts of interest among certain directors and officers; lack of liquidity for shareholders of the Company; litigation risk; and the factors identified under the caption ‘Risk Factors’ in the Company’s public disclosure documents. Readers are cautioned against attributing undue certainty to forward-looking statements or forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or forward-looking information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements or information, other than as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276385

• Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.

• Results provide clinical evidence that CardiolRx reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression.

• The ARCHER data strengthen the scientific and clinical rationale for Cardiol’s lead Phase III program in recurrent pericarditis (MAVERIC) and support broader development across inflammatory cardiac conditions.

• Chronic inflammation is a central driver of adverse cardiac remodeling and heart failure, yet there are currently no approved therapies that directly target this underlying biology.

Toronto, Ontario–(Newsfile Corp. – December 1, 2025) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol‘ or the ‘Company‘), a clinical-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced new and comprehensive data from ARCHER, a randomized double-blind, placebo-controlled, multi-center Phase II clinical trial of CardiolRx in patients with acute myocarditis. The data show meaningful improvements in cardiac MRI (CMR) measures of myocardial recovery in patients with acute myocarditis, a potentially fatal condition caused by viral infections, autoimmune diseases, immune checkpoint inhibitor therapy to treat cancers, and exposure to cardiotoxic substances.

‘The ARCHER results show that CardiolRx can drive meaningful structural recovery in the hearts of patients with acute myocarditis,’ said Dr. Andrew Hamer, Chief Medical Officer and Head of Research & Development of Cardiol Therapeutics. ‘We are seeing in these patients the same beneficial cardiac changes we previously observed in multiple pre-clinical heart failure models, strengthening our confidence in CardiolRx as a potential therapy across multiple inflammatory cardiac conditions.’

Key findings from the ARCHER trial presented this past weekend included a marked 9.2-gram reduction in left ventricular (LV) mass (p=0.0117), along with reductions in two parameters that directly impact the heart’s LV mass: extracellular volume (ECV), a measure that reflects inflammation and fibrosis outside the heart muscle cells and intercellular volume (ICV), a measure of swelling and enlargement of the heart cells. Together, these results indicate a meaningful structural improvement in the heart that is consistent with recovery from inflammation-driven edema.

The magnitude of LV mass reduction observed in ARCHER is similar to that achieved with several commonly prescribed blockbuster drugs for heart failure, obesity, and hypertension-treatments proven to improve long-term survival and reduce major cardiac events. Observing this level of structural cardiac benefit in myocarditis patients who were neither obese nor hypertensive underscores the strong clinical relevance of ARCHER’s findings and their potential importance for future treatment options, as it indicates a meaningful resolution of cardiac inflammation.

The ARCHER data were presented on November 29, 2025, by Dr. Leslie T. Cooper, Jr., Chair of the Department of Cardiovascular Medicine at Mayo Clinic in Florida and Co-Chair of the Steering Committee for the ARCHER trial, at the Annual Meeting of the European Society of Cardiology Working Group on Myocardial & Pericardial Disease in Trieste, Italy.

‘ARCHER was an important, well-designed, and well-executed clinical trial. The positive changes in CMR measurements are exciting-most notably the reduction in LV mass, consistent with the numerical reductions in both ECV and ICV,’ commented Dr. Cooper. ‘These findings reinforce our original hypothesis that this innovative treatment strategy can attenuate myocardial inflammation and edema. ARCHER’s results provide sound rationale for advancing the clinical development of this novel therapy in conditions of the myocardium characterized by edema, fibrosis, and remodeling, including the growing challenge of immune checkpoint inhibitor-induced myocarditis, which can be fatal.’

‘The results of this study are the first that I am aware of to demonstrate improvements in key measures of cardiac structure and remodeling in patients with myocarditis. The results constitute exciting clinical proof of concept that supports advancing the clinical development of this novel therapeutic approach for inflammatory cardiac conditions, including heart failure,’ said Dr. Dennis M. McNamara, Professor of Medicine at the University of Pittsburgh, Director of the Center for Heart Failure Research at the University of Pittsburgh Medical Center, and Chair of the ARCHER trial. ‘On behalf of the ARCHER Steering Committee, I would like to extend our sincere gratitude to the patients who participated in the study; to their families and caregivers for their invaluable support; and to the clinical trial site investigators and staff, members of the international Steering Committee, and the Data and Safety Monitoring Committee, whose exemplary efforts in patient recruitment, clinical care, trial execution, monitoring, and oversight were instrumental in achieving the compelling findings of the ARCHER trial.’

‘The ARCHER results fortify our confidence in our broader pipeline,’ said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. ‘They reinforce the growing recognition that cardiac inflammation is a treatable driver of disease progression, supporting the potential of CardiolRx, currently being evaluated in the ongoing Pivotal Phase III MAVERIC trial in recurrent pericarditis, and additionally CRD-38, our next-generation small molecule designed to target the same pathway in chronic conditions such as heart failure with preserved ejection fraction. Taken together, these findings strengthen the scientific rationale behind both programs and point to a clear path for developing new therapies for a range of inflammatory heart diseases.’

Key Findings from ARCHER

CardiolRx improved multiple CMR measures of myocardial recovery, heart size, and function following 12 weeks of treatment.

• LV mass, which represents the weight/thickness of the heart’s left ventricle muscle and is increased when the heart works harder, was significantly reduced in the patients receiving CardiolRx (the active group) at 121.1 grams (g), compared to those patients receiving placebo at 130.3g, a difference of -9.2g (p=0.0117).
• Extracellular volume, representing the space outside the heart tissue cells that expands with edema or fibrosis, was reduced in the active group at 33.6 milliliters (mL), compared to placebo at 37.3mL, a difference of -3.7mL (p=0.0538).
• Intracellular volume, reflecting the volume of the heart muscle cells themselves that becomes elevated with cellular swelling during inflammation, was reduced in the active group at 85.6mL, compared to placebo at 91.2mL, a difference of -5.6mL (p=0.0928).
• Left atrial end systolic volume (LAESV) was reduced in the active group compared to placebo with a difference of -8.1mL (p=0.0376). LAESV is a measure of atrial size and workload that when elevated reflects dysfunction, higher pressure, or inflammation, but when reduced indicates improved heart relaxation and stress.
• Left ventricular end diastolic volume (LVEDV), which represents the heart’s left ventricle size, compliance, and function, and may become elevated because of inflammation or fibrosis, was reduced in the active group compared to placebo with a difference of -7.4mL (p=0.0981). Reduction of LVEDV reflects improved ventricular function or reverse cardiac remodelling (the process of changes in the heart’s size, shape, and function in response to injury or increased stress).

The active and placebo groups were well matched at baseline-patients averaged 39 years of age, were predominantly male (81%), largely reported prior viral-like illness (>70%), showed preserved left-ventricular function, and the vast majority presented with chest pain (95%). Nearly all patients were hospitalized for the index myocarditis event (96.0%), with median hospital stays of five days in both groups and similar ICU durations. All results were adjusted for any baseline differences.

Consistent with prior clinical studies in inflammatory heart disease, CardiolRx was shown to be safe and well tolerated, with treatment emergent adverse events leading to discontinuation equal between the groups and balanced serious adverse event rates.

Company Webcast Conference Call Details

Cardiol will host a webcast and conference call today at 8:30 a.m. EST. Management will review ARCHER trial results, discuss implications for future development, and outline next steps for Cardiol’s inflammatory heart disease programs. To participate by telephone, please dial 877-346-6112 (Canada and the United States) or +1-848-280-6350 (International). The conference call with also be broadcast live online through a listen-only webcast (with slides), which will be posted under ‘Events & Presentations’ in the Investors section of the Cardiol website (cardiolrx.com/investors/events-presentations/) and archived for approximately 90 days.

About Acute Myocarditis

Acute myocarditis is an inflammatory disease of the myocardium with a highly variable clinical presentation, ranging from mild flu-like symptoms or chest pain to severe heart failure, life-threatening arrhythmias, or sudden cardiac death. Although this condition is most commonly caused by viral infections, it can also result from autoimmune diseases, hypersensitivity reactions, or exposure to cardiotoxic substances. Patients hospitalized with the condition experience an average seven-day length of stay and a 4 – 6% risk of in-hospital mortality, with average hospital charge per stay estimated at $110,000 in the United States.

About the Phase II ARCHER Study

ARCHER enrolled 109 patients from leading cardiovascular research centers in the United States, France, Brazil, and Israel, and investigated the safety, tolerability, and impact of CardiolRx on myocardial recovery in patients presenting with acute myocarditis. The design and rationale for ARCHER were published on June 27, 2024, in the journal, ESC Heart Failure (pubmed.ncbi.nlm.nih.gov/38937900/).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company advancing late-stage, anti-inflammatory, and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program is also studying CardiolRx, specifically in acute myocarditis-an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation intended for use in heart failure, including through the initiation of the first-in-human clinical evaluation, the potential implications of the results of the ARCHER trial including the possibility that CardiolRx can drive meaningful structural recovery in the hearts of patients with acute myocarditis, the Company’s belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx, strengthen the scientific and clinical rationale for Cardiol’s lead Phase III program in recurrent pericarditis, and strongly support advancing the clinical development of CardiolRx and CRD-38 for the treatment of inflammatory cardiac disorders including cardiomyopathies, heart failure, and myocarditis, and the intention of the Company to review the ARCHER trial data, discuss implications for future development, and outline next steps regarding the Company’s inflammatory heart disease programs. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276405

(TheNewswire)

Toronto, Ontario TheNewswire – December 1, 2025 Noble Mineral Exploration Inc. ( ‘Noble’ or the ‘Company’ ) (TSX-V:NOB, FRANKFURT: NB7, OTCQB:NLPXF) is pleased to announce the signing of a drill contract for 1000 meters in two holes located in Carnegie Township near Timmins, Ontario, Canada.  The two 500-meter holes have been located to follow up on drilling done in 2022 and in order to further define the geology and mineralization.

An additional 1000m (2 holes) have been scheduled for Southwest Carnegie Township in early 2026, after freeze-up, due to swampy conditions at the proposed drill site.

The technical content of this release has been reviewed and approved by Wayne Holmstead, P.Geo., an independent Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects .

About Noble Mineral Exploration Inc.

Noble Mineral Exploration Inc. is a Canadian-based junior exploration company, which has holdings of securities in Canada Nickel Company Inc., Homeland Nickel Inc., East Timmins Nickel Inc. (20%), and its interest in the Holdsworth gold exploration property in the area of Wawa, Ontario.

Noble holds mineral and/or exploration rights in ~70,000ha in Northern Ontario and ~24,000ha elsewhere in Quebec upon which it plans to generate option/joint venture exploration programs.

Noble holds mineral rights and/or exploration rights in ~18,000 hectares in the Timmins-Cochrane areas of Northern Ontario known as Project 81, ~2,215 hectares in Thomas Twp/Timmins, as well as an additional 20% interest in ~38,700 hectares in the Timmins area and ~175 hectares of mining claims in Central Newfoundland. Project 81 hosts diversified drill-ready gold, nickel-cobalt and base metal exploration targets at various stages of exploration. Noble also holds ~4,600 hectares in the Nagagami Carbonatite Complex and its ~3,200 hectares in the Boulder Project both near Hearst, Ontario.  ~3,700 hectares in the Buckingham Graphite Property, ~10,152 hectares in the Havre St Pierre  Nickel, Copper, PGM property, and ~1,573 hectares in the Cere-Villebon Nickel, Copper, PGM property, ~569 hectare Uranium/Rare Earth property (Chateau), ~461 hectare Uranium/Molybdenum property (Taser North),  ~4,465 hectares REE Mehmet Property, and the ~3300 hectare Gull Lake REE Property all of which are in the Province of Quebec.

https://www.noblemineralexploration.com

Noble’s common shares trade on the TSX Venture Exchange under the symbol ‘NOB’.

Cautionary Statement

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

The foregoing information may contain forward-looking statements relating to the future performance of Noble Mineral Exploration Inc. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially from the Company’s plans and expectations. These plans, expectations, risks and uncertainties are detailed herein and from time to time in the filings made by the Company with the TSX Venture Exchange and securities regulators.  Noble Mineral Exploration Inc. does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts: H. Vance White, President

Phone:        416-214-2250

Fax:                416-367-1954

Email: info@noblemineralexploration.com

Investor Relations: ir@noblemineralexploration.com

Copyright (c) 2025 TheNewswire – All rights reserved.

KEY POINTS

• Homerun also announces that a new patent application has been filed for a subject invention resulting under the Cooperative Research and Development Agreement (CRADA No. CRD-23-24168) between Homerun and Alliance. The invention relates to a thermal energy storage (TES) system integrated with silica sand purification that results in advanced silica material that can be utilized in technology and energy end-uses for example battery anode precursor materials.

• Under the commercialization plan, Homerun Energy’s AI Energy Management System (EMS) will be integrated into the NREL particle-based thermal energy storage systems.

Reno, Nevada–(Newsfile Corp. – December 1, 2025) – Homerun Energy USA, Inc. (‘Homerun’ or the ‘Company’) a newly formed 100% owned subsidiary of Homerun Resources, Inc. (TSXV: HMR,OTC:HMRFF) (OTCQB: HMRFF) is pleased to announce that the Company has signed an Intellectual Property Agreement (‘IPA’) with Alliance for Sustainable Energy, LLC (‘Alliance’), management and operating contractor of the U.S. Department of Energy’s National Renewable Energy Laboratory (‘NREL’).

Brian Leeners, CEO of Homerun stated, ‘This IPA is the culmination of a two-year partnership between Homerun and NREL and is the realization of the synergy across the Homerun vertical strategy where our unique silica sand facilitates particle-based energy storage and silica calcination purification integrated with the Homerun Energy EMS to complete and advance the potential commercial offerings. Having achieved this level of integration on the capital expended to date, is a complement to the vision and creativity within our electrification strategy. Working with the team at NREL, lead by Zhiwen Ma, has fast-tracked the development cycle to where we are today at the precipice of commercialization into a global electrification revolution demanding economic long-life, long duration energy storage and industrial heating/cooling solutions.’

Homerun entered a CRADA with NREL (CRD-23-24168), and subsequently formed a U.S. based startup company, Homerun Energy USA, Inc. that is securing the option for the license to certain intellectual property belonging to Alliance, which was brought into the IPA and/or developed under the CRADA (‘Option’). Alliance is the owner of the Alliance Intellectual Property and is granting the Option through the IPA, for Homerun to advance the technologies toward commercial application. The option period runs for twelve (12) months, subject to ongoing negotiations during that period.

As a part of any license, Alliance requires Homerun to use commercially reasonable efforts to bring Alliance Intellectual Property to market through a thorough, vigorous, and diligent commercialization program. The NREL particle-based thermal energy storage system was originally developed using funding from ARPA-E, and the IP portfolio consists of many issued patents and patent applications filed in the U.S., Canada, and Brazil.

Figure A shows the diagram of long duration energy storage technology using sand-based thermal energy storage developed in the ARPA-E supported project that is under the license agreement.

Figure A. Sand-Thermal Energy Storage System Consists of: (1) Particle-Lifting Device, (2) Charging Electric Heater, (3) Internally Insulated Storage Silos, (4) Discharge Heat Exchanger, and (5) Combined Cycle Power Generation.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4082/276424_08c27c92d41a1970_001full.jpg

Homerun also announces that a new patent application has been filed for the invention resulting under the Cooperative Research and Development Agreement (CRADA No. CRD-23-24168) between Homerun and Alliance. The invention relates to a thermal energy storage (TES) system integrated with silica sand purification processing.

Key relevant aspects of the innovation include:

• A system comprising a sand thermal energy storage process and a silica purification process where silica sand is used as the thermal energy storage medium and as a final product of the silica purification process.

• The storage charging/discharging devices are contained in a single system, and silica calcination and/or drying devices are contained within that system.

Sustainable Impact

• Synergize energy storage with silica purification and maximizes energy utilization.

• Efficiency: recovers and reuses process heat for both internal plant operations and external industrial customers (pulp & paper, food, chemicals, metallurgical applications and data centres).

• Flexible Revenue: the dual-purpose system opens multiple profit channels in power sales, industrial process heat contracts, and processed silica materials supply.

Under the commercialization plan for the NREL Energy Storage System, Homerun Energy will integrate its advanced AI energy management and control system (EMS). Homerun’s technology is designed to operate across devices and brands to optimize energy capture, maximize storage efficiency and enable smarter, more sustainable energy use. By integrating AI into the edge Hub and into the cloud, Homerun empowers the end-user to better monitor, control and predict energy generation, usage and needs, enhancing performance while reducing costs and environmental impact and enabling advanced services such as energy trading.

Figure B shows the innovative modular sand thermal energy storage that Homerun is looking to bring to the market as a first step of commercializing the sand energy storage method.

Figure B. Modular Sand Thermal Energy Storage System for Heat and/or Power.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4082/276424_08c27c92d41a1970_002full.jpg

About Homerun (https://www.homerunenergy.com/ and https://homerunresources.com/) Homerun Energy USA, Inc (Reno, NV) is a 100% subsidiary of Homerun Resources, Inc.

Homerun Resources Inc. (TSXV: HMR,OTC:HMRFF) is building the silica-powered backbone of the energy transition across four focused verticals: Silica, Solar, Energy Storage, and Energy Solutions. Anchored by a unique high-purity low-iron silica resource in Bahia, Brazil, Homerun transforms raw silica into essential products and technologies that accelerate clean power adoption and deliver durable shareholder value.

• ⁠Silica: Secure supply and processing of high-purity low-iron silica for mission-critical applications, enabling premium solar glass and advanced energy materials.

• Solar: Development of Latin America’s first dedicated 1,000 tonne per day high-efficiency solar glass plant and the commercialization of antimony-free solar glass designed for next-generation photovoltaic performance.

• Energy Storage: Advancement of long-duration, silica-based thermal storage systems and related technologies to decarbonize industrial heat and unlock grid flexibility.

• ⁠Energy Solutions: AI-enabled energy management, control systems, and turnkey electrification solutions that reduce costs and optimize renewable generation for commercial and industrial customers.

With disciplined execution, strategic partnerships, and an unwavering commitment to best-in-class ESG practices, Homerun is focused on converting milestones into markets-creating a scalable, vertically integrated platform for clean energy manufacturing in the Americas.

On behalf of the Board of Directors of
Homerun Resources Inc.

‘Brian Leeners’

FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

The information contained herein contains ‘forward-looking statements’ within the meaning of applicable securities legislation. Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. Any statements that express predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be ‘forward-looking statements’.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276424

Copper Quest Exploration Inc. (CSE: CQX,OTC:IMIMF; OTCQB: IMIMF; FRA: 3MX) (‘ Copper Quest ‘ or the ‘ Company ‘) is pleased to announce it has entered into a strategic partnership with U.S. based Exploration Technologies Inc. (‘ ExploreTech ‘) to deploy generative artificial intelligence across its project portfolio, beginning with the Kitimat Copper-Gold Project in British Columbia. The Company has also completed an initial work program at Kitimat and expanded its geological thesis based on historical datasets and updated field observations.

EXPLORETECH PARTNERSHIP OVERVIEW

ExploreTech integrates drilling, IP/magnetics, geochemistry, structural data, satellite imagery, and field observations into a unified 3D geological framework. The system generates thousands of subsurface model scenarios, evaluates probability, and optimizes drill plans for the highest-priority copper-gold targets. The technology has been successfully applied on multiple porphyry systems.

ExploreTech will collaborate with Copper Quest’s team on their portfolio of projects, with the Kitimat Copper-Gold Project being processed first.

ExploreTech will:

• Conduct AI-driven reprocessing and inversion of historical geophysical datasets
• Generate geological simulations to resolve concealed intrusive centers, alteration, and mineralization
• Produce probability-ranked target clusters
• Recommend optimized drillhole placement, orientations, and depths
• Integrate Copper Quest’s 2025 soil and rock geochemical data
• Provide a fully integrated drill targeting package for the Kitimat Project

The technology is ideally suited for covered porphyry systems such as Kitimat, where limited outcrop and shallow till cover obscure significant subsurface features.

KITIMAT WORK PROGRAM SUMMARY

Copper Quest engaged Hardline Exploration to complete a reconnaissance field program at Kitimat in November 2025, collecting soil and rock samples, documenting structural and lithological observations, and assessing access routes.

Field Highlights

• 24 soil samples collected along two soil lines (assays pending)
• Eight rock samples collected from outcrop and historical working exposures (assays pending)
• Bedrock consists of quartz monzonite
• Strong silicification
• 5–10% disseminated fine-grained pyrite
• Traces of chalcopyrite
• Local molybdenum
• Orange-rusty weathering, consistent with sulphide-rich alteration
• Access roads on the claims are intact
• Historical logging/exploration roads provide excellent future drill access

These observations are indicative of the presence of a large altered intrusive system consistent with a productive porphyry environment.

HISTORICAL DRILLING: CONFIRMATION OF A SIGNIFICANT CU-AU SYSTEM

Exploration at Kitimat dates to the late 1960s. The most significant work was completed by Decade Resources Ltd. in 2010, which drilled 16 diamond holes totaling 4,437.5 m at the Jeannette Cu-Au Zone.

Notable Drill Intervals (2010)

• Hole J-7: 117.07 m @ 1.03 g/t Au and 0.54% Cu (from 1.52 m to 118.60 m)
• Hole J-1: 103.65 m @ 1.00 g/t Au and 0.55% Cu (from 9.15 m to 112.80 m)
• Hole J-2: 107.01 m @ 0.80 g/t Au and 0.45% Cu (from 6.10 m to 113.11 m)
• Hole J-8: 112.20 m @ 0.41 g/t Au and 0.33% Cu (from 11.89 m to 124.09 m)
  (Kruchkowski, E., 2010, BC Assessment Report #31807)

Interpretation

• Long, continuous, near-surface copper-gold intervals
• Mineralization remains open at depth
• Geological indicators suggest the system extends laterally beyond the drilled area
• Vectoring from 2010 drilling trends northeast toward a concealed porphyry center
• No systematic follow-up drilling has been completed in 15 years

Copper Quest believes these results represent a strong opportunity for discovery within a larger, buried hydrothermal system.

2010 Drilling – Collar Location Data:

MANAGEMENT COMMENTS

Brian Thurston, CEO of Copper Quest

‘The Kitimat Project hosts excellent, historic mineralized intervals interpreted to represent a buried porphyry system. The long, near-surface copper-gold intercepts drilled in 2010 remain open and were never systematically followed up. ExploreTech’s AI platform will allow us to integrate decades of fragmented datasets and directly target the buried porphyry center that the geological evidence strongly supports.’

Alex Miltenberger, CEO of ExploreTech

‘Our generative AI technology evaluates thousands of geological and geophysical scenarios to identify the most probable mineralized centers. We look forward to supporting Copper Quest in unlocking the full potential of their portfolio of projects starting with the Kitimat Copper-Gold project.’

NEXT STEPS

1. Deliver all historical datasets to ExploreTech
2. Begin AI-driven modeling and geophysical inversion
3. Integrate 2025 soil and rock geochemical results
4. Receive probability-ranked target clusters and drillhole trajectories
5. Finalize the 2025–2026 exploration and drilling program
6. Assess applying ExploreTech’s technology to additional Copper Quest properties

NON-BROKERED FULLY-SUBSCRIBED FINANCING

Copper Quest is pleased to announce that the Company has arranged a non-brokered private placement financing of 10,142,104 common shares of the Company to be issued on a flow-through basis (the ‘ Flow-Through Shares ‘) at a price of $0.19 per Flow-Through Share for aggregate gross proceeds of $1,927,000 (the ‘ Flow-Through Offering ‘).

The Flow-Through Offering is fully subscribed and finder’s fees will be applicable.

Each Flow-Through Share will be designated as either a ‘flow-through share’ or ‘critical mineral flow-through share’, as applicable, within the meanings of the Income Tax Act (Canada). The gross proceeds from the issuance of the Flow-Through Shares will be used to incur ‘Canadian exploration expenses’ that qualify as ‘flow-through mining expenditures’ or ‘flow-through critical mineral mining expenditures’, as applicable, as such terms are defined in the Income Tax Act (Canada), which will be renounced to subscribers with an effective date no later than December 31, 2026, all in accordance with the Income Tax Act ( Canada ) and applicable provincial legislation.

All securities to issued in connection with the Flow-Through Offering will be subject to a statutory hold period of four months from the date of issuance in accordance with applicable Canadian securities legislation. Closing of the Flow-Through Offering is anticipated to occur within a week from the date hereof and is subject to the receipt of all requisite approvals, including the acceptance of the Canadian Securities Exchange.

An insider of the Company will be participating in the Offering. The issuance of Flow-Through Shares to an insider will constitute a ‘related party transaction’ as defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (‘ MI 61-101 ‘). The Company will be relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the securities to be purchased by the insider, nor the consideration for the securities to be paid by such insider, will exceed 25% of the Company market capitalization. The Company will not file a material change report in respect of the related party transaction at least 21 days before the closing of the Flow-Through Offering, which the Company deems to be reasonable in order to complete the Offering in a timely manner.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the ‘ U.S. Securities Act ‘), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States.

ABOUT EXPLORETECH

ExploreTech is a geological technology company specializing in AI-driven geological modeling, geophysical inversion, and drill-target optimization. Its platform is designed to rapidly identify concealed intrusive centers and mineralized systems with improved accuracy and efficiency.

COPPER: GLOBAL DEMAND & SUPPLY

Globally, copper demand continues to surge, driven by electrification, electric vehicles, renewable energy, and the massive expansion of AI and data center infrastructure. Yet supply remains constrained, with declining grades at existing mines, limited new discoveries, and prolonged permitting timelines. The resulting supply-demand imbalance underscores the importance of advancing new porphyry discoveries in stable jurisdictions like the U.S. and Canada. Copper Quest is aligned with this macro trend, positioning its North American portfolio of projects to become part of the next generation of copper and critical mineral discoveries.

QUALIFIED PERSON STATEMENT

The scientific and technical information in this news release has been reviewed and approved by Jeremy Hanson, P.Geo., a Qualified Person as defined under National Instrument 43-101 Standards of Disclosure for Mineral Projects (‘ NI 43-101 ‘). Mr. Hanson is independent of Copper Quest Exploration Inc. for the purposes of NI 43-101 and has verified the data disclosed in this news release, including sampling methods, geological descriptions, and historical exploration information.

ABOUT Copper Quest Exploration Inc.

Copper Quest (CSE: CQX,OTC:IMIMF; OTCQB: IMIMF; FRA: 3MX) is focused on building shareholder value through project acquisition, and exploration and development of its North American Critical Mineral portfolio of assets. The Company’s land package currently comprises five projects that span over 40,000+ hectares in great mining jurisdictions as well as the Kitimat Cu-Au Project and the past-producing Alpine Gold Mine that are both pending acquisition following due diligence.

Copper Quest has a 100% interest in the Stars Property, a porphyry copper-molybdenum discovery, covering 9,693 hectares in central British Columbia’s Bulkley Porphyry Belt. Contiguous to the Stars Property, Copper Quest has a 100% interest in the 5,389 hectare Stellar Property. CQX also has an earn-in option up to 80% and joint-venture agreement on the 4,700 hectare porphyry copper-molybdenum Rip Project, also in the Bulkley Porphyry Belt.

Copper Quest has a 100% interest in the Nekash Copper-Gold Project, a porphyry exploration opportunity located in Lemhi County, Idaho, along the prolific Idaho-Montana porphyry copper belt that hosts world-class systems such as Butte and CUMO. The project is fully road-accessible via maintained U.S. highways and forest service roads and currently consists of 70 unpatented federal lode claims covering 585 hectares.

Copper Quest has a 100% interest in the Thane Project located in the Quesnel Terrane of Northern BC which spans over 20,658 ha with 10 high-priority targets identified demonstrating significant copper and precious metal mineralization potential.

Copper Quest’s leadership and advisory teams are senior mining industry executives who have a wealth of technical and capital markets experience and a strong track record of discovering, financing, developing, and operating mining projects on a global scale. Copper Quest is committed to sustainable and responsible business activities in line with industry best practices, supportive of all stakeholders, including the local communities in which it operates. The Company’s common shares are principally listed on the Canadian Stock Exchange under the symbol ‘CQX’. For more information on Copper Quest, please visit the Company’s website at www.copper.quest.

On behalf of the Board of Copper Quest Exploration Inc.

Brian Thurston, P.Geo.
Chief Executive Officer and Director
Tel: 778-949-1829

For further information contact:

Investor Relations
info@copper.quest

Forward Looking Information

This news release contains certain ‘forward-looking information’ and ‘forward-looking statements’ (collectively, ‘ forward-looking statements ‘) within the meaning of applicable securities legislation. All statements, other than statements of historical fact included herein, including without limitation, statements regarding the terms and completion of the Flow-Through Offering, the payment of finder’s fees and issuance of Finder’s Warrants, the anticipated closing date and the planned use of proceeds of the Flow-Through Offering, and future operations and activities of Copper Quest, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as ‘expects’, ‘anticipates’, ‘believes’, ‘intends’, ‘estimates’, ‘potential’, ‘possible’, and similar expressions, or statements that events, conditions, or results ‘will’, ‘may’, ‘could’, or ‘should’ occur or be achieved. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability to obtain regulatory approval of the Flow-Through Offering, risks associated with possible accidents and other risks associated with mineral exploration operations, the risk that the Company will encounter unanticipated geological factors, risks associated with the interpretation of exploration results, the possibility that the Company may not be able to secure permitting and other governmental clearances necessary to carry out the Company’s exploration plans, the risk that the Company will not be able to raise sufficient funds to carry out its business plans, and the risk of political uncertainties and regulatory or legal changes that might interfere with the Company’s business and prospects. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these items. The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this press release, and does not accept responsibility for the adequacy or accuracy of this release.